<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Mol. Biosci.</journal-id>
<journal-title>Frontiers in Molecular Biosciences</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Mol. Biosci.</abbrev-journal-title>
<issn pub-type="epub">2296-889X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">633526</article-id>
<article-id pub-id-type="doi">10.3389/fmolb.2021.633526</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Molecular Biosciences</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Structural Analysis of Anti-Hapten Antibodies to Identify Long-Range Structural Movements Induced by Hapten Binding</article-title>
<alt-title alt-title-type="left-running-head">Al Qaraghuli et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Structural Analysis of Anti-Hapten Antibodies</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Al Qaraghuli</surname>
<given-names>Mohammed M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/950291/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kubiak-Ossowska</surname>
<given-names>Karina</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1268516/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ferro</surname>
<given-names>Valerie A.</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/64491/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mulheran</surname>
<given-names>Paul A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1268500/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<label>1</label>Department of Chemical and Process Engineering, University of Strathclyde, <addr-line>Glasgow</addr-line>, <country>United&#x20;Kingdom</country>
</aff>
<aff id="aff2">
<label>2</label>SiMologics Ltd., The Enterprise Hub, <addr-line>Glasgow</addr-line>, <country>United&#x20;Kingdom</country>
</aff>
<aff id="aff3">
<label>3</label>Department of Physics, University of Strathclyde, <addr-line>Glasgow</addr-line>, <country>United&#x20;Kingdom</country>
</aff>
<aff id="aff4">
<label>4</label>Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, <addr-line>Glasgow</addr-line>, <country>United&#x20;Kingdom</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/109435/overview">Petri Kursula</ext-link>, University of Bergen, Norway</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/102149/overview">Christian Cambillau</ext-link>, Aix-Marseille Universit&#xe9;, France</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/147393/overview">Tommi Antero Kajander</ext-link>, University of Helsinki, Finland</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Mohammed M. Al Qaraghuli, <email>mohammed.al-qaraghuli@strath.ac.uk</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Structural Biology, a section of the journal Frontiers in Molecular Biosciences</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>24</day>
<month>03</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>8</volume>
<elocation-id>633526</elocation-id>
<history>
<date date-type="received">
<day>25</day>
<month>11</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>02</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Al Qaraghuli, Kubiak-Ossowska, Ferro and Mulheran.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Al Qaraghuli, Kubiak-Ossowska, Ferro and Mulheran</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>Antibodies are well known for their high specificity that has enabled them to be of significant use in both therapeutic and diagnostic applications. Antibodies can recognize different antigens, including proteins, carbohydrates, peptides, nucleic acids, lipids, and small molecular weight haptens that are abundantly available as hormones, pharmaceuticals, and pesticides. Here we focus on a structural analysis of hapten-antibody couples and identify potential structural movements originating from the hapten binding by comparison with unbound antibody, utilizing 40 crystal structures from the Protein Data Bank. Our analysis reveals three binding surface trends; S1 where a pocket forms to accommodate the hapten, S2 where a pocket is removed when the hapten binds, and S3 where no pockets changes are found. S1 and S2 are expected for induced-fit binding, whereas S3 indicates that a pre-existing population of optimal binding antibody conformation exists. The structural analysis reveals four classifications of structural reorganization, some of which correlate to S2 but not to the other binding surface changes. These observations demonstrate the complexity of the antibody-antigen interaction, where structural changes can be restricted to the binding sites, or extend through the constant domains to propagate structural changes. This highlights the importance of structural analysis to ensure successful and compatible transformation of small antibody fragments at the early discovery stage into full antibodies during the subsequent development stages, where long-range structural changes are required for an Fc effector response.</p>
</abstract>
<kwd-group>
<kwd>antibody</kwd>
<kwd>antigen binding fragments (Fab)</kwd>
<kwd>hapten</kwd>
<kwd>RMSD</kwd>
<kwd>RMSF</kwd>
<kwd>allosteric movement</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>The immune system represents a major defensive mechanism that protects vertebrates against pathogen invasion. Within this system, lymphocytes synthesize cell surface receptors or secrete glycoproteins, known as antibodies, which specifically bind to foreign molecules (<xref ref-type="bibr" rid="B7">Alberts et&#x20;al., 2002</xref>). Antibodies are immunoglobulins that can recognize various types of antigen, including proteins, carbohydrates, peptides, nucleic acids, lipids, and small molecular weight (&#x3c;1,000&#xa0;Da) haptens. The focus of this article will be on haptens since they are ubiquitously found as hormones, pharmaceuticals, and pesticides (<xref ref-type="bibr" rid="B6">Al Qaraghuli et&#x20;al., 2015</xref>).</p>
<p>An antibody of class IgG is normally composed of two light and two heavy chains linked together by disulphide bonds. These heavy and light chains create two identical antigen-binding fragments (Fabs), each contain the first two domains of the heavy (V<sub>H</sub> and C<sub>H1</sub>) and light (V<sub>L</sub> and C<sub>L</sub>) chains, and one crystallizable region fragment (Fc), each comprising C<sub>H2</sub> and C<sub>H3</sub> domains (<xref ref-type="bibr" rid="B44">Porter, 1959</xref>; <xref ref-type="bibr" rid="B50">Ryle and Porter, 1959</xref>). The Fc region can propagate a series of immunological responses through the heavy chains, whilst the Fab fragments are responsible for antigen recognition through variable sites known as complementarity determining regions (CDRs) (<xref ref-type="bibr" rid="B34">Kubota et&#x20;al., 2009</xref>). Each variable (V<sub>H</sub> and V<sub>L</sub>) domain contains three CDRs, and the resulting six CDRs collectively represent the antigen binding&#x20;sites.</p>
<p>The antibody-antigen interaction process is dictated by a multitude of non-covalent forces (<xref ref-type="bibr" rid="B54">Van Oss, 1995</xref>), and supported by complementarity in the binding interface charge and shape (<xref ref-type="bibr" rid="B6">Al Qaraghuli et&#x20;al., 2015</xref>). The surface topography of these binding sites normally differs according to the antigen type (<xref ref-type="bibr" rid="B58">Webster et&#x20;al., 1994</xref>). Somatic gene-recombination and mutations, heavy and light chain dimerization, and antibody class-switching, are mechanisms that can craft the malleable binding sites to accommodate a wide range of antigens (<xref ref-type="bibr" rid="B27">Jacob et&#x20;al., 1991</xref>; <xref ref-type="bibr" rid="B36">MacLennan, 1991</xref>; <xref ref-type="bibr" rid="B39">Muramatsu et&#x20;al., 2000</xref>; <xref ref-type="bibr" rid="B1">Abhinandan and Martin, 2010</xref>). These shapes include flat surfaces to grasp large protein surfaces, pockets to accommodate small haptens, and grooves to enclose peptides (<xref ref-type="bibr" rid="B35">MacCallum et&#x20;al., 1996</xref>).</p>
<p>Even with the well-known specificity of antibodies, some antigen-specific antibodies can still simultaneously interact with different structurally unrelated antigens (<xref ref-type="bibr" rid="B11">Bentley et&#x20;al., 1990</xref>; <xref ref-type="bibr" rid="B9">Arevalo et&#x20;al., 1993</xref>; <xref ref-type="bibr" rid="B43">Pokkuluri et&#x20;al., 1994</xref>; <xref ref-type="bibr" rid="B31">Keitel et&#x20;al., 1997</xref>; <xref ref-type="bibr" rid="B33">Krishnan et&#x20;al., 2008</xref>; <xref ref-type="bibr" rid="B52">Tapryal et&#x20;al., 2013</xref>). This antibody poly-specificity could be a method implemented by the body to enlarge the immune-system conformational repertoire and enhance foreign pathogen recognition. Different variability-upon-binding phenomena are frequently described, like ligand induced-fit: the binding of an antibody to an antigen causes a change in the shape of the antibody binding sites to enhance the binding efficiency (<xref ref-type="bibr" rid="B48">Rini et&#x20;al., 1992</xref>; <xref ref-type="bibr" rid="B12">Bosshard, 2001</xref>; <xref ref-type="bibr" rid="B49">Rosen et&#x20;al., 2005</xref>; <xref ref-type="bibr" rid="B32">Keskin, 2007</xref>; <xref ref-type="bibr" rid="B56">Wang et&#x20;al., 2013</xref>); antibody isomerism: preferential ligand binding to a pre-existing subpopulation of antibody isomers that exist in equilibrium (<xref ref-type="bibr" rid="B21">Foote and Milstein, 1994</xref>; <xref ref-type="bibr" rid="B23">Hansson et&#x20;al., 1997</xref>; <xref ref-type="bibr" rid="B20">Foote, 2003</xref>; <xref ref-type="bibr" rid="B17">Debler et&#x20;al., 2008</xref>); promiscuity: the ability of an antibody to bind to structurally different antigens through different binding sites (<xref ref-type="bibr" rid="B10">Backes et&#x20;al., 2003</xref>; <xref ref-type="bibr" rid="B29">James et&#x20;al., 2003</xref>; <xref ref-type="bibr" rid="B28">James and Tawfik, 2003</xref>; <xref ref-type="bibr" rid="B18">Dimitrov et&#x20;al., 2007</xref>, <xref ref-type="bibr" rid="B19">2012</xref>; <xref ref-type="bibr" rid="B30">Kang and Warren, 2007</xref>; <xref ref-type="bibr" rid="B15">Bryson et&#x20;al., 2009</xref>); and moonlighting: an antibody having different functions results from binding to different antigens (<xref ref-type="bibr" rid="B37">Martin, 2014</xref>; <xref ref-type="bibr" rid="B26">Irani, 2016</xref>). These phenomena can be facilitated through allosteric structural movements of the antibody loops (<xref ref-type="bibr" rid="B42">Piekarska et&#x20;al., 2006</xref>; <xref ref-type="bibr" rid="B51">Sela-Culang et&#x20;al., 2012</xref>; <xref ref-type="bibr" rid="B13">Bowen and Casadevall, 2016</xref>; <xref ref-type="bibr" rid="B60">Yang et&#x20;al., 2017</xref>), which can propagate signals from variable to constant regions to induce Fc-mediated effector functions. The generated effector functions can then induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).</p>
<p>Despite the significant interest by the biopharmaceutical industry to generate and craft antibodies&#x2019; binding sites with the highest affinity, it is equally crucial to understand the conformational changes beyond these binding sites. This will ensure successful and compatible transformation of small antibody fragments (single-chain variable fragment (scFv) or Fab fragments) at early developmental stages to full antibodies. Accordingly, understanding the allosteric model might assist us to comprehend the structural signaling that occurs beyond the pocket binding sites of anti-hapten antibodies.</p>
<p>In a recent study, we examined the structural differences in anti-protein Fab crystal structures caused by binding to the antigens (<xref ref-type="bibr" rid="B4">Al Qaraghuli et&#x20;al., 2020</xref>). This revealed three classifications for the observed changes that we called class B1, B2 and B3. In B1, the binding of the protein antigen to the Fab causes a distortion to the Fab&#x2019;s diamond-like structure along with a movement in the linker region that connects the Fab to the Fc in the full antibody. This is the expected behavior when a large protein interacts across the Fab binding surface, resulting in significant changes that propagate through the heavy chains to create a potential allosteric signal. However, in class B2 we found no pronounced distortion of the Fab but still recognized the potential allosteric signal. Class B3 was even more surprising, with no distortion and no apparent structural movements, although we note that this was found for only one protein antigen that was derived from synthetic phage display library without any requirement for an effector response in its development.</p>
<p>In this paper, we extend our analysis to anti-hapten Fab crystal structures of IgG antibodies retrieved from the Protein Data Bank (PDB). These Fabs were crystallized in free and antigen-complexed formats. It is well known that anti-hapten antibodies display pocket binding-sites to accommodate small molecular weight haptens. However, it is not completely clear how these pockets are generated in response to these haptens. Therefore, it was necessary to analyze the binding surfaces of these antibodies, and classify them into different surface (S) classes accordingly. Moreover, haptens are expected to cause smaller changes in the antibody binding sites when compared to large molecular weight proteins. So another essential point to investigate is related to whether our previous binding (B) classification, conducted on anti-protein antibodies (<xref ref-type="bibr" rid="B4">Al Qaraghuli et&#x20;al., 2020</xref>), can be extended to haptens. Our analyses have also included comparison of the B and S classes to identify any favorable correlation among these classes. Together, these provide a comprehensive insight to the different effects hapten binding has on antibody structure. In particular, the recognition of potential conformational changes can provide crucial information for the successful development of novel antibodies, since the absence of long-range structural changes beyond the binding site indicate no concomitant changes to functionality and thus no allostery.</p>
</sec>
<sec sec-type="methods" id="s2">
<title>Methods</title>
<sec id="s2-1">
<title>Antibody Selection and Sequence Analysis</title>
<p>Forty crystal structures of Fab fragments were retrieved from the PDB and organized into couples, so that free antibody could be compared to the hapten antigen-bound form. We included all structures with acceptable resolution (<inline-formula id="inf1">
<mml:math id="minf1">
<mml:mrow>
<mml:mi mathvariant="normal">&#x2272;</mml:mi>
<mml:mn>3</mml:mn>
</mml:mrow>
</mml:math>
</inline-formula>&#xb0;&#xc5;) in the analysis to allow a confident classification of the surface topography and structural changes (<xref ref-type="bibr" rid="B38">McDonald and Thornton, 1994</xref>; <xref ref-type="bibr" rid="B8">Almagro, 2004</xref>; <xref ref-type="bibr" rid="B47">Raghunathan et&#x20;al., 2012</xref>)<sup>.</sup> Antibody structures were considered similar if their chains (heavy and light) shared 100% sequence identity, and had similar sequence to the antigen bound form. The effect of crystal contacts in the PDB structures used in this analysis were considered negligible, because the structural changes were analyzed in terms of backbone movements rather than the side-chains that are most likely affected by crystal formation. Therefore, the assumption is made that the crystal contacts in the PDB structures do not strongly affect the backbone structure; this assumption can be explored further in future&#x20;work.</p>
<p>Amino acid positions were sequentially numbered to avoid conflicts at residue positions, and to ensure accurate structural measurements. A few sequences were omitted from the study at different stages (such as 1JNH, 1JN6, and 1JGL) due to the fact that these polypeptide chains were not continuous. In total, 40 crystal structures (32 mouse, four fully human, and four chimeric with human C<sub>H1</sub> domain) were identified and selected; all the potential sequences in the PDB were considered, so that the analysis is comprehensive within the stated selection criteria. A few of the selected antibodies were crystalized against more than one antigen, and full details of these crystal structures are summarized in <xref ref-type="sec" rid="s9">Supplementary Tables&#x20;S1.1</xref>.</p>
<p>The Fab sequences were retrieved from the PDB, and analyzed using BioEdit Sequence Alignment Editor, version 7.2.5 (<xref ref-type="bibr" rid="B22">Hall, 1999</xref>). ClustalW Multiple alignment was used to align sequences of the same type (heavy or light chains) and origin (human or mouse). All the gathered and analyzed sequences are listed in <xref ref-type="sec" rid="s9">Supplementary Tables S3</xref>. The three loops in the variable domains were denoted CDRs 1&#x2013;3, and the three loops in the constant domains (CH and CL) were named C_Loop 1&#x2013;3, according to their location throughout the sequence from the N-terminal to the C-terminal of the entire&#x20;chain.</p>
</sec>
<sec id="s2-2">
<title>Root-Mean-Square Distance (RMSD) and Fluctuations (RMSF)</title>
<p>The structural variability of similar proteins or different conformations of the same protein can be quantified using RMSD (<xref ref-type="bibr" rid="B16">Carugo and Pongor, 2001</xref>).</p>
<p>Here the RMSD is defined as<disp-formula id="e1">
<mml:math id="me1">
<mml:mrow>
<mml:mi>R</mml:mi>
<mml:mi>M</mml:mi>
<mml:mi>S</mml:mi>
<mml:mi>D</mml:mi>
<mml:mo>&#x3d;</mml:mo>
<mml:msqrt>
<mml:mrow>
<mml:mfrac>
<mml:mrow>
<mml:msubsup>
<mml:mstyle displaystyle="true">
<mml:mo>&#x2211;</mml:mo>
</mml:mstyle>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>&#x3d;</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
<mml:mi>N</mml:mi>
</mml:msubsup>
<mml:msup>
<mml:mrow>
<mml:mrow>
<mml:mo>&#x7c;</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mover accent="true">
<mml:mi>r</mml:mi>
<mml:mo>&#x2192;</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>A</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>&#x2212;</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mover accent="true">
<mml:mi>r</mml:mi>
<mml:mo>&#x2192;</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>F</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mo>&#x7c;</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mn>2</mml:mn>
</mml:msup>
</mml:mrow>
<mml:mi>N</mml:mi>
</mml:mfrac>
</mml:mrow>
</mml:msqrt>
</mml:mrow>
</mml:math>
<label>(1)</label>
</disp-formula>where N is the number of (backbone) atoms in the protein structure and <inline-formula id="inf2">
<mml:math id="minf2">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mover accent="true">
<mml:mi>r</mml:mi>
<mml:mo>&#x2192;</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>A</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula> , <inline-formula id="inf3">
<mml:math id="minf3">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mover accent="true">
<mml:mi>r</mml:mi>
<mml:mo>&#x2192;</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>F</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
</inline-formula> is the position of the <italic>i</italic>th atom in the antigen-bound (A) and free (F) Fab structure. In order to calculate the RMSD, the two protein structures to be examined are firstly considered as rigid bodies, then overlapped (aligned) using only translations and rotations. The RMSDs of the backbone atoms were only calculated for particular regions, such as variable (residues 1&#x2013;105), linker (106&#x2013;113) and constant (114&#x2013;218) domains, as well as each couple for the entire antibody chain (residues 1&#x2013;218). The side chains of residues were excluded because insignificant differences in their orientations could introduce additional&#x20;noise.</p>
<p>RMSF is another useful tool to track structural changes in proteins, where the RMSD is calculated and reported for each protein residue in the compared structure. It is regularly denoted as &#x201c;fluctuations&#x201d; as it calculates a time-average amplitude of residue movement (fluctuation) from each compared position in the aligned structures. Despite the wide adaptation of RMSF in dynamic structures, it can be used in static structures as it provides RMSDs calculated per particular residue. With this form of RMSF, it is easy to track the residues that are most responsible for the total conformational alterations, the creation of pockets and, for potential allosteric signaling. Therefore, following <xref ref-type="disp-formula" rid="e1">Eq. 1</xref> we define RMSF in <xref ref-type="disp-formula" rid="e2">Eq. 2</xref>, and where symbols have the same meaning as before.<disp-formula id="e2">
<mml:math id="me2">
<mml:mrow>
<mml:mi>R</mml:mi>
<mml:mi>M</mml:mi>
<mml:mi>S</mml:mi>
<mml:msub>
<mml:mi>F</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>&#x3d;</mml:mo>
<mml:mrow>
<mml:mo>&#x7c;</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mover accent="true">
<mml:mi>r</mml:mi>
<mml:mo>&#x2192;</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>A</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>&#x2212;</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mover accent="true">
<mml:mi>r</mml:mi>
<mml:mo>&#x2192;</mml:mo>
</mml:mover>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>F</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mo>&#x7c;</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math>
<label>(2)</label>
</disp-formula>
</p>
</sec>
<sec id="s2-3">
<title>Variable and Constant Domain Orientation</title>
<p>The orientation of the V<sub>H</sub>/V<sub>L</sub> domains vs. C<sub>H1</sub>/C<sub>L</sub> domains was examined to complement the RMSD/RMSF measurements. One conserved cysteine residue (Cys) was chosen in each of the V<sub>L</sub>, C<sub>L</sub>, V<sub>H</sub>, and C<sub>H1</sub> domains (See <italic>Domain Orientation</italic>). Moreover, one conserved amino acid in each of the V<sub>L</sub>/C<sub>L</sub> and V<sub>H</sub>/C<sub>H1</sub> linkers was also selected. These amino acids were serine (Ser), arginine (Arg), and glutamine (Gln) in the heavy, light (K), and light (<italic>&#x3bb;</italic>) chains, respectively (<xref ref-type="fig" rid="F1">Figure&#x20;1</xref>). The six amino acids selected in each Fab are highlighted in turquoise in the full sequences file (<xref ref-type="sec" rid="s9">Supplementary S3</xref>). The angles of the heavy (Cys-Ser-Cys) and light (Cys-Gln-Cys or Cys-Arg-Cys) chains were measure by PyMOL (The PyMOL Molecular Graphics System, Version 1.7.4 Schr&#xf6;dinger, LLC.). The distances between the Cys residues in the heavy and light chains were also measured by PyMOL.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Angle measurements. The IgG antibody can be divided into three fragments: two Fab regions and one Fc region. The enlarged Fab region illustrates the amino acid positions used to calculate the domain orientational changes. The selected amino acids are denoted as Cys: cysteine, Ser: serine, Gln: glutamine (in <italic>&#x3bb;</italic> light chains), and Arg: arginine (in K light chains).</p>
</caption>
<graphic xlink:href="fmolb-08-633526-g001.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="results|discussion" id="s3">
<title>Results and Discussion</title>
<sec id="s3-1">
<title>Antibody Binding Surfaces</title>
<p>Analysis of anti-hapten Fabs can provide information about the changes in the binding surfaces upon antigen recognition. Anti-hapten antibodies have shown preference to recognize their targeted antigens through the formation of pockets in their binding sites. Comparison of the free vs. antigen-bound crystal structures Fabs (23 couples) have shown three binding surface (S1&#x2013;3) trends:<list list-type="simple">
<list-item>
<p>&#x2022; <bold>S1:</bold> the presence of a pocket binding site on the antibody-antigen complex but not on the antibody-free counterparts, as can be observed in three mouse Fab couples (1Q0Y_1Q0X, 3CFB_3CFC, and 1I9J_1I9I) and two human Fab couples (1D6V_1D5B and 1AJ7_2RCS). Illustration of these figures can be observed in <xref ref-type="sec" rid="s9">Supplementary Figures S2.1, S2.10, S2.18, S2.22, and&#x20;S2.23</xref>.</p>
</list-item>
<list-item>
<p>&#x2022; <bold>S2:</bold> the presence of a pocket binding site on the antibody-free structure, but not on the antibody-antigen complex, as observed in three couples of mouse Fabs (1QYG_1RFD, 1Q72_1RFD, and 2AJV_2AJU). <xref ref-type="sec" rid="s9">Supplementary Figures S2.4A, S2.5, and S2.12</xref> show these three couples.</p>
</list-item>
<list-item>
<p>&#x2022; <bold>S3:</bold> there is no (or slight) apparent change in the binding sites as can be noticed in the remaining 15 couples of anti-hapten&#x20;Fabs.</p>
</list-item>
</list>
</p>
<p>An example from each of the three groups is demonstrated in <xref ref-type="fig" rid="F2">Figure&#x20;2</xref>, and detailed observations are shown in <xref ref-type="sec" rid="s9">Supplementary Figure S2</xref>. The antibody (3CFB; <xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>) can bind the antigen [4-(4-styryl-phenylcarbamoyl)-butyric acid] through side chain of amino acid Q96, and CDR H3 of the bound form has slightly moved inwards to support the pocket formation, as illustrated in <xref ref-type="sec" rid="s9">Supplementary Figure S.2.1F</xref>. In contrast, the antigen (cocaine) can bind the antibody (1Q72; <xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>) through residue Y32 of the light chain, and CDR H3 of the bound form has moved away from the binding site center to cause an opening of the binding pocket (<xref ref-type="sec" rid="s9">Supplementary Figure S.2.4F</xref>). Whilst, the third example was demonstrated by the antibody (4COX; <xref ref-type="fig" rid="F2">Figure&#x20;2C</xref>) that can bind the antigen (methotrexate) through two amino acids at the light chain (E39 and Y41) and one amino acid at the heavy chain (N36) (<xref ref-type="sec" rid="s9">Supplementary Figure S.2.17F</xref>). The three residues are located at the bottom of the pocket, and no major changes were noticed by comparing the antigen-bound verses the free form of the antibody.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Binding sites surfaces. The binding surfaces can be grouped into three categories. In S1, there is a pocket binding site on the antibody-antigen complex and not on the antibody-free counterparts, as shown in <bold>(A)</bold>. In S2, there is a pocket binding site on the antibody-free structure and not on the antibody-antigen complex, as can be observed in <bold>(B)</bold>. In S3, there is no (or only slight) change in the binding sites as shown in <bold>(C)</bold>. The heavy and light chains were colored as denoted in the figure, and the hapten antigen is shown as a red line drawing.</p>
</caption>
<graphic xlink:href="fmolb-08-633526-g002.tif"/>
</fig>
<p>Antibodies can generally bind antigens through multiple conformational states rather than a rigid lock and key method. Although structural changes between free and antigen-bound antibodies were usually correlated with an induced-fit mechanism, structural evidence for a pre-existing equilibrium was also identified (<xref ref-type="bibr" rid="B29">James et&#x20;al., 2003</xref>). This was evident in analyzing anti-IL1&#x3b2; and anti-IL6 Fabs and scFvs that have shown the core of the antigen binding sites, in particular the CDR3 loops, to exist in multiple conformational states (<xref ref-type="bibr" rid="B3">Addis et&#x20;al., 2014</xref>). This behavior seems to be a conserved feature of many high affinity protein-protein interaction sites, suggesting a key role in the formation of tight protein complexes (<xref ref-type="bibr" rid="B57">Waters et&#x20;al., 2007</xref>; <xref ref-type="bibr" rid="B55">Veverka et&#x20;al., 2009</xref>; <xref ref-type="bibr" rid="B24">Holdsworth et&#x20;al., 2012</xref>). Consequently, slight structural changes between the free and bound structures would be expected if the free conformation that was crystallized is the same one bound to the antigen. These slight changes were observed in group S3 (15 couples), supporting this picture.</p>
<p>On the other hand, significant changes are expected if a different pre-existing antigen-unbound conformation was crystallized. These structural changes could reflect the anti-hapten Fabs of groups S1 (5 couples) and S2 (3 couples). A distinction between these two groups can be achieved through analysis of their RMSD/RMSF differences, and heavy and light chain packing (see below).</p>
</sec>
<sec id="s3-2">
<title>Conformational Changes Upon Binding (RMSD Analysis)</title>
<p>The conformational changes were determined by calculating the total RMSD difference between the antibody-antigen complex and the antibody-free counterparts. Out of the analyzed 23 couples, seven have shown more deviations in the light chains when compared to heavy chains, and the opposite was observed in the remaining 16 couples (<xref ref-type="table" rid="T1">Table&#x20;1</xref>). In addition, the constant domains (C<sub>H1</sub> and C<sub>L</sub>) of these Fabs have demonstrated more movements than the variable domains (V<sub>H</sub> and V<sub>L</sub>), as reported in <xref ref-type="table" rid="T1">Table&#x20;1</xref>; and the quantitative information is summarized in <xref ref-type="sec" rid="s9">Supplementary Table&#x20;S1.2</xref>.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>RMSD comparison.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Heavy/light chains</th>
<th align="center">Anti-hapten (23 couples)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Light chain &#x3e; heavy chain</td>
<td align="center">7<break/>(3CFD_3CFE, 1JNN_1JNL, 1KEL_1KEM, 2AJY_2AJU, 2AK1_2AJU, 2AJV_2AJU, and 4OCX_4OCY)</td>
</tr>
<tr>
<td align="left">Light chain &#x3c; heavy chain</td>
<td align="center">Remaining 16 couples</td>
</tr>
</tbody>
</table>
<table>
<thead valign="top">
<tr>
<td align="left">
<bold>Light chain</bold>
</td>
<td align="left"/>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">&#x2003;CL &#x3c; VL</td>
<td align="center">9<break/>(3CFB_3CFC, 3CFD_3CDE, 1KEL_1KEM, 1Q0Y_1Q0X, 2AJX_2AJU, 2AJY_2AJU, 2AK1_2AJU, and 2AJV_2AJU, 2AJZ_2AJU)</td>
</tr>
<tr>
<td align="left">&#x2003;CL &#x3d; VL</td>
<td align="center">1<break/>(2AJS_2AJU)</td>
</tr>
<tr>
<td align="left">&#x2003;CL &#x3e; VL</td>
<td align="center">Remaining 13 couples</td>
</tr>
</tbody>
</table>
<table>
<thead valign="top">
<tr>
<td align="left">
<bold>Heavy chain</bold>
</td>
<td align="left"/>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">&#x2003;CH &#x3c; VH</td>
<td align="center">7<break/>(1UB5_1UB6, 2AJS_2AJU, 2AJX_2AJU, 2AJY_2AJU, 2AK1_2AJU, and 2AJV_2AJU, and 2AJZ_2AJU)</td>
</tr>
<tr>
<td align="left">&#x2003;CH &#x3e; VH</td>
<td align="center">Remaining 16 couples</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The high movements of the constant domains relative to the variable domains and to each other can increase the likelihood of a suitable V<sub>H</sub>-V<sub>L</sub> relative orientation and signal propagation from the variable to constant domains (<xref ref-type="bibr" rid="B40">Padlan, 1994</xref>; <xref ref-type="bibr" rid="B59">Wilson and Stanfield, 1994</xref>; <xref ref-type="bibr" rid="B14">Braden and Poljak, 1995</xref>). For instance, these movements were reflected in the complement activation of two antibodies that differed only in their V<sub>H</sub> domain (<xref ref-type="bibr" rid="B25">Horgan et&#x20;al., 1992</xref>). In other work, two human monoclonal antibodies, having similar variable domains but different constant domains, were shown to bind their target with significantly different affinities (<xref ref-type="bibr" rid="B45">Pritsch et&#x20;al., 1996</xref>). Furthermore, a comparison of the binding affinity of Fabs to smaller variable fragments (scFv) by Adachi et&#x20;al. also revealed a large difference in affinity (<xref ref-type="bibr" rid="B2">Adachi et&#x20;al., 2003</xref>). We have noticed these movements through analysis of an entire antibody in molecular dynamics simulations (<xref ref-type="bibr" rid="B5">Al Qaraghuli et&#x20;al., 2018</xref>), and in a comprehensive analysis of anti-protein antibodies (<xref ref-type="bibr" rid="B4">Al Qaraghuli et&#x20;al., 2020</xref>). So our findings suggest that the high movement of the constant domains could be a reflection of essential structural movements that can help trigger the immune response. These movements are expected to be greater in the heavy chain when compared to light chains, since the Fab-to-Fc movements occur in these heavy chains and through the main Fab-Fc linker.</p>
</sec>
<sec id="s3-3">
<title>Conformational Changes Upon Binding (RMSF Analysis)</title>
<p>The RMSF of each amino acid position in the 40 crystal structures, which represent 23 free antibody and antigen-complexed couples, were also analyzed. In general, four different classifications (B1&#x2013;4) for structural change upon binding were identified, following the classification scheme identified with anti-protein Fabs (<xref ref-type="bibr" rid="B4">Al Qaraghuli et&#x20;al., 2020</xref>):<list list-type="simple">
<list-item>
<p>&#x2022; <bold>B1:</bold> Random movements throughout the entire Fab illustrated by five anti-hapten couples (1NGP_1NGQ, 2CGR_1CGS, 1D6V_1D5B, 1AJ7_2RCS, and 1FL6_1FL5).</p>
</list-item>
<list-item>
<p>&#x2022; <bold>B2:</bold> Specific movement at the C_Loop<sub>1</sub> of six anti-hapten couples (3CFB/3CFC, 4OCX_4OCY, 1I9J_1I9I, 3LS4_3LS5, 1KEL_1KEM, and 1C5C_1C5B).</p>
</list-item>
<list-item>
<p>&#x2022; <bold>B3:</bold> Specific movements at the CDRs of eight anti-hapten couples (2AJV_2AJU, 2AJS_2AJU, 2AJX_2AJU, 2AJY_2AJU, 2AJZ_2AJU, 2AK1_2AJU, 1Q72_1RFD, and 1QYG_1RFD).</p>
</list-item>
<list-item>
<p>&#x2022; <bold>B4:</bold> Random, but very low movements as shown in four anti-hapten couples 3CFD_3CFE, 1UB5_1UB6, 1JNN_1JNL, and 1Q0Y_1Q0X.</p>
</list-item>
</list>
</p>
<p>Examples from each trend were selected from the anti-hapten Fabs, as illustrated in <xref ref-type="fig" rid="F3">Figure&#x20;3</xref>, and <xref ref-type="sec" rid="s9">Supplementary Figure S2</xref>. The RMSF was calculated for the entire heavy and light chains, and also separately for their specific domains (VH, CH, VL, and CL) to separate out contributions from the domain orientation changes reported&#x20;below.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>RMSF analysis. RMSF measurements were analyzed for anti-hapten Fabs. Classes B1, B2, B3, and B4 are represented by 2CGR_1CGS, 3CFD_3CFE, 2AJV_2AJU, and 1KEL_1KEM, respectively. The RMSF comparison was performed on the total chain (heavy and light) and independently on their specific domains (V<sub>H</sub>, C<sub>H1</sub>, V<sub>L</sub>, and C<sub>L</sub>). Heavy chain loops were highlighted in grey and light chain loops were highlighted in yellow. The <italic>x</italic>-axis denotes the amino acid positions of either the heavy or light chain, permitting them to be examined in the same figure.</p>
</caption>
<graphic xlink:href="fmolb-08-633526-g003.tif"/>
</fig>
<p>These results can reflect changes in the constant domains as well as the variable domains. These changes, however, were either random, with big (B1) or small (B4) movements, or at specific positions (CDRs and/or C_Loop1 in classes B3/B2). We note that this range of structural change agrees with our previous analysis of protein-binding Fabs, with the addition of B4 which is unique to certain anti-hapten&#x20;Fabs.</p>
<p>Movements at the CDRs are expected to reflect the antigen binding process. Furthermore, <xref ref-type="bibr" rid="B51">Sela-Culang et&#x20;al. (2012)</xref> have shown that the C_Loop<sub>1</sub> was the highest moving loop, which in B2 has moved even more than CDRH3 in B3. Various studies have correlated the C_Loop1, which is located at C<sub>H1</sub> domain, to detected changes in binding, because it was recognized as the only region with sequence diversity among the examined antibodies (<xref ref-type="bibr" rid="B45">Pritsch et&#x20;al., 1996</xref>; <xref ref-type="bibr" rid="B46">Pritsch et&#x20;al., 2000</xref>; <xref ref-type="bibr" rid="B53">Torres et&#x20;al., 2007</xref>). Furthermore, the C_Loop<sub>1</sub> was suggested to be intrinsically disordered, associated in the interaction between the heavy and light chains, and linked to complement binding (<xref ref-type="bibr" rid="B51">Sela-Culang et&#x20;al., 2012</xref>). We note that this loop is close to the main hinge region, and a conformational change in this loop may affect the relative orientation of the C<sub>H1</sub> domain vs. the entire Fc, thus influencing the overall effector function of the Fc region (<xref ref-type="bibr" rid="B41">Patil et&#x20;al., 2010</xref>; <xref ref-type="bibr" rid="B51">Sela-Culang et&#x20;al., 2012</xref>). Therefore, structural changes in the C_Loop<sub>1</sub> (in the Fab region) could stimulate changes in the Fc region to facilitate triggering of the immune response. The random movements of B1 and B4 can be better understood through an analysis of the various domain orientations, as will be discussed in the following section.</p>
</sec>
<sec id="s3-4">
<title>Domain Orientation</title>
<p>The heavy and light chain angles (<xref ref-type="fig" rid="F1">Figure&#x20;1</xref>) of the anti-hapten Fabs have shown large changes in class B1, as observed in 1NGP/1NGQ, 2CGR/1CGS, 1FL6/1FL5, 1D6V/1D5B and 1AJ7/2RCS (<xref ref-type="table" rid="T2">Table&#x20;2</xref> and <xref ref-type="sec" rid="s9">Supplementary Table S4</xref>). These large changes originate from a reduction in the angles between the heavy chains and an increase between the light chains, and are in line with the distance changes between the selected Cys residues on each domain. The linker-linker distance of this class has also increased in the bound form when compared to their free counterparts. The small angle changes of class B4 were also reflected in the relatively low changes in the Cys-Cys and linker-linker distances. Likewise, both class B3 (with large CDR movement) and class B2 (large C_Loop1 movement) have shown relatively low angle changes, and this can be observed in the remaining crystal structure pairs (Supplementary Table&#x20;4).</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Binding conformational change classes.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left"/>
<th align="center">PDB ID</th>
<th align="center">Crystal form</th>
<th align="center">Magnitude of average angle change (<sup>o</sup>)</th>
<th align="center">Binding surface class</th>
<th align="center">Structural change class</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">1</td>
<td align="center">3CFB</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">9.25</td>
<td align="center">S1</td>
<td align="center">B2</td>
</tr>
<tr>
<td align="left">2</td>
<td align="center">3CFC</td>
<td align="left">Antibody</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">3</td>
<td align="center">3CFD</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">0.55</td>
<td align="center">S3</td>
<td align="center">B4</td>
</tr>
<tr>
<td align="left">4</td>
<td align="center">3CFE</td>
<td align="left">Antibody</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">5</td>
<td align="center">1UB5</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">0.95</td>
<td align="center">S3</td>
<td align="center">B4</td>
</tr>
<tr>
<td align="left">6</td>
<td align="center">1UB6</td>
<td align="left">Antibody</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">7</td>
<td align="center">1Q72</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">0.75</td>
<td align="center">S2</td>
<td align="center">B3</td>
</tr>
<tr>
<td align="left">8</td>
<td align="center">1QYG</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">0.45</td>
<td align="center">S2</td>
<td align="center">B3</td>
</tr>
<tr>
<td align="left">9</td>
<td align="center">1RFD</td>
<td align="left">Antibody</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">10</td>
<td align="center">1JNN</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">0.75</td>
<td align="center">S3</td>
<td align="center">B4</td>
</tr>
<tr>
<td align="left">11</td>
<td align="center">1JNL</td>
<td align="left">Antibody</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">12</td>
<td align="center">1KEL</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">1</td>
<td align="center">S3</td>
<td align="center">B2</td>
</tr>
<tr>
<td align="left">13</td>
<td align="center">1KEM</td>
<td align="left">Antibody</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">14</td>
<td align="center">1NGP</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">8.55</td>
<td align="center">S3</td>
<td align="center">B1</td>
</tr>
<tr>
<td align="left">15</td>
<td align="center">1NGQ</td>
<td align="left">Antibody</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">16</td>
<td align="center">2CGR</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">19.75</td>
<td align="center">S3</td>
<td align="center">B1</td>
</tr>
<tr>
<td align="left">17</td>
<td align="center">1CGS</td>
<td align="left">Antibody</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">18</td>
<td align="center">1Q0Y</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">0.65</td>
<td align="center">S1</td>
<td align="center">B4</td>
</tr>
<tr>
<td align="left">19</td>
<td align="center">1Q0X</td>
<td align="left">Antibody</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">20</td>
<td align="center">2AJS</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">2.35</td>
<td align="center">S3</td>
<td align="center">B3</td>
</tr>
<tr>
<td align="left">21</td>
<td align="center">2AJV</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">0.95</td>
<td align="center">S2</td>
<td align="center">B3</td>
</tr>
<tr>
<td align="left">22</td>
<td align="center">2AJX</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">4.7</td>
<td align="center">S3</td>
<td align="center">B3</td>
</tr>
<tr>
<td align="left">23</td>
<td align="center">2AJY</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">4.2</td>
<td align="center">S3</td>
<td align="center">B3</td>
</tr>
<tr>
<td align="left">24</td>
<td align="center">2AJZ</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">1.85</td>
<td align="center">S3</td>
<td align="center">B3</td>
</tr>
<tr>
<td align="left">25</td>
<td align="center">2AK1</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">4.15</td>
<td align="center">S3</td>
<td align="center">B3</td>
</tr>
<tr>
<td align="left">26</td>
<td align="center">2AJU</td>
<td align="left">Antibody</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">27</td>
<td align="center">4OCX</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">1.25</td>
<td align="center">S3</td>
<td align="center">B2</td>
</tr>
<tr>
<td align="left">28</td>
<td align="center">4OCY</td>
<td align="left">Antibody</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">29</td>
<td align="center">1I9J</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">0.5</td>
<td align="center">S1</td>
<td align="center">B2</td>
</tr>
<tr>
<td align="left">30</td>
<td align="center">1I9I</td>
<td align="left">Antibody</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">31</td>
<td align="center">3LS4</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">1.25</td>
<td align="center">S3</td>
<td align="center">B2</td>
</tr>
<tr>
<td align="left">32</td>
<td align="center">3LS5</td>
<td align="left">Antibody</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">33</td>
<td align="center">1FL6</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">5.9</td>
<td align="center">S3</td>
<td align="center">B1</td>
</tr>
<tr>
<td align="left">34</td>
<td align="center">1FL5</td>
<td align="left">Antibody</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">35</td>
<td align="center">1C5C</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">0.5</td>
<td align="center">S3</td>
<td align="center">B2</td>
</tr>
<tr>
<td align="left">36</td>
<td align="center">1C5B</td>
<td align="left">Antibody</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">37</td>
<td align="center">1D6V</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">22.4</td>
<td align="center">S1</td>
<td align="center">B1</td>
</tr>
<tr>
<td align="left">38</td>
<td align="center">1D5B</td>
<td align="left">Antibody</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">39</td>
<td align="center">1AJ7</td>
<td align="left">Antigen-antibody</td>
<td align="char" char=".">30.65</td>
<td align="center">S1</td>
<td align="center">B1</td>
</tr>
<tr>
<td align="left">40</td>
<td align="center">2RCS</td>
<td align="left">Antibody</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
</tbody>
</table>
</table-wrap>
<p>Binding Surface class S2 (with a pocket binding site on the antibody-free structure, but not on the antibody-antigen complex) is associated with B3 (with CDR changes only). In addition, none of class B3 have shown binding surface class S1 (pockets on the antibody-antigen complex, but no pocket on the free antibody form). Therefore, these results could suggest that large CDR movements are associated with the closure of the pockets in the antibody-antigen complexes, and not involved in the opening of these pockets if the antibody-free structure displays a non-pocket binding&#x20;site.</p>
<p>The presence of pockets in the antibody-antigen complexes, but not in the free form (S1) or the presence of pockets on both the free and bound forms (S3) were associated with either classes B1 or B4 (random movements) or class B2 (C_Loop1 specific movements). Consequently, the presence of a pocket in the binding sites of the antibody-bound form could be correlated to movements in C_Loop1 and/or with high movements in the entire antibody. However, the high movement of C_Loop1, and the generation of these pockets in the antibody-bound form could also be a result of an induced-fit mechanism or by binding to one of the pre-existing free conformations.</p>
<p>Taken together, these data illustrate the complexity of the antibody-antigen interaction process that could be restricted to the binding sites, or extended through the constant domains to propagate structural changes beyond these sites. In order to further illustrate these concepts, we now examine and discuss one specific example in detail.</p>
</sec>
<sec id="s3-5">
<title>Specific Analysis of Anti-Cocaine Antibody</title>
<p>We analyzed the antibody 7A1 and compared it to its set of antigen-bound forms. This antibody hydrolyses cocaine to produce the non-psychoactive metabolites ecgonine methyl ester and benzoic acid. Crystal structures of 7A1 Fab (2AJU) and six complexes with substrate cocaine (2AJV), the transition state analogue (2AJX), the products ecgonine methyl ester and benzoic acid together (2AJY) and individually (2AJZ and 2AK1), as well as with heptaethylene glycol (2AJS), have all been resolved by <xref ref-type="bibr" rid="B61">Zhu et&#x20;al. (2006)</xref> and are all available from the PDB. These authors identified significant structural rearrangements that occur along the reaction pathway, which they proposed to be limited to the binding site (<xref ref-type="bibr" rid="B61">Zhu et&#x20;al., 2006</xref>). This suggestion was based on identifying modest CDR loop movements (up to 2.3&#xa0;&#xc5;), along with substantial side chain rearrangements (up to 9&#xa0;&#xc5;) that have altered the shape and size (&#x223c;320&#x2013;500&#xa0;&#xc5;<sup>3</sup>) of the antibody active site from open (for the substrate) to closed (transition state) to open (product states) (<xref ref-type="bibr" rid="B61">Zhu et&#x20;al., 2006</xref>).</p>
<p>Antibody 7A1 is IgG2a-Kappa, and the binding sites transition from open (2AJV) to closed (2AJX) to open (2AJZ, 2AJY, and 2AK1) can be observed in <xref ref-type="fig" rid="F4">Figure&#x20;4</xref>. This closure can be attributed to the twisting of the benzene ring of the transitional state antigen of 2AJX when compared to cocaine in 2AJV. The cocaine bound crystal structure (2AJU) also shows closure of a very small binding pocket in the center of the binding sites of the remaining free and bound crystal structures (<xref ref-type="fig" rid="F4">Figure&#x20;4</xref>). Zhu et&#x20;al. have crystalized antibody 7A1 in different antigen-bound forms, and comprehensively reported these atomistic interactions (<xref ref-type="bibr" rid="B61">Zhu et&#x20;al., 2006</xref>).</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Binding sites of antibody 7A1. Illustration of the crystal structures of antibody 7A1 as free form (2AJU) and six antigen bound states against Ecgonine methyl ester (2AJZ), Ecgonine methyl ester and benzoic acid (2AJY), Cocaine (2AJV), Benzoic acid (2AK1), 3-(hydroxy-phenyl-phosphinoyloxy)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid methyl ester (2AJX), and PEG330 (2AJS). The heavy and light chains of the antibody-free form of 2AJU were colored as red and yellow, respectively. Whilst green (heavy chains) and blue (light chains) was used to color the antigen bound structures. Chemical structure of each of the antigens was depicted at the bottom of each crystal structure.</p>
</caption>
<graphic xlink:href="fmolb-08-633526-g004.tif"/>
</fig>
<p>RMSD comparison of the bound vs. free forms has confirmed suggestions by Zhu et&#x20;al. that the VH and VL domains have moved more than the C<sub>H1</sub> and C<sub>L</sub> counterparts. In addition, the light chains of 2AJY, 2AK1, and 2AJV have moved more than the heavy chains (<xref ref-type="sec" rid="s9">Supplementary Table S1.2</xref>). Therefore, this movement could be attributed to the binding of ecgonine methyl ester to the light chains, and the benzene ring to the heavy chain, which cause further light chains movements.</p>
<p>Despite the high movement of the variable domains (V<sub>H</sub> and V<sub>L</sub>), the RMSF analyses have also shown additional movement of the constant domains (C<sub>H1</sub> and C<sub>L</sub>) (<xref ref-type="fig" rid="F5">Figure&#x20;5</xref>). 2AJV has shown specific movement of CDRL1, CDRL3 and an area next to CDRH1 to accommodate cocaine through an open binding state (<xref ref-type="fig" rid="F5">Figure&#x20;5</xref>). Whilst in the transition state of 2AJX, the active site demonstrates a closed form, in which the CDRH2 progress toward the active site (<xref ref-type="fig" rid="F5">Figure&#x20;5</xref> and <xref ref-type="sec" rid="s9">Supplementary Figure S.2.1.13</xref>). The remaining five antigen-bound states have demonstrated general fluctuation with greater focus on the loops (<xref ref-type="fig" rid="F5">Figure&#x20;5</xref>). An important region for structural analysis is C_Loop1 of the heavy chain. The movement of this loop was between 1 and 2&#xa0;&#xc5; in all bound states except the main anti-cocaine antibody 2AJV (&#x223c;0.55&#xa0;&#xc5;). This reduced movement of C_Loop1 in 2AJV could be correlated with the disappearance of the small pocket at the center of the groove binding site (<xref ref-type="fig" rid="F4">Figure&#x20;4</xref>). We note that the scale of the C_Loop1 changes is much lower than found in classes B1 and B2 where clear evidence of signal propagation is found. Indeed, all these crystal structures have shown class B3 structural changes, and S3 surfaces apart from 2AJV (class S2), which is the crystal structure of the cocaine bound antibody. These structural changes match the function of this antibody in hydrolyzing cocaine rather than propagation of an immune response.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>RMSF analysis of antibody 7A1. RMSF measurements were analyzed for the six bound states of antibody 7A1. Blue dotted line was placed at RMSF 1&#xa0;&#xc5; to allow easier comparison. The bound states were 2AJS, 2AJY, 2AJV, D 2AJZ, 2AJX, and 2AK1.</p>
</caption>
<graphic xlink:href="fmolb-08-633526-g005.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="conclusion" id="s4">
<title>Conclusion</title>
<p>In this paper we have extended our analysis of Fab structural changes induced by antigen binding from proteins (<xref ref-type="bibr" rid="B4">Al Qaraghuli et&#x20;al., 2020</xref>) to haptens. Crystal structures of anti-hapten antibodies were retrieved from the PDB, and comprehensive analyses were conducted to examine their binding sites and the structural changes caused by antigen binding.</p>
<p>We have identified three classifications of binding surface conformational changes induced by hapten interactions:<list list-type="simple">
<list-item>
<p>S1: The hapten binding causes the creation of a pocket on the Fab binding surface, enabled by the movement of the entire chains.</p>
</list-item>
<list-item>
<p>S2: The hapten binding removes a pocket from the Fab binding surface, through changing the CDR conformation.</p>
</list-item>
<list-item>
<p>S3: The binding surface remains pocket-free before and after hapten binding.</p>
</list-item>
</list>
</p>
<p>Classifications S1 and S2 are to be expected with an induced-fit picture of how antibodies bind to hapten antigens. The prevalence of S3 indicates that this picture is not complete, and that some Fabs can exist in high-affinity conformations to bind their hapten targets. The latter picture is reminiscent of the affinity shown by antibodies to much larger proteins with larger binding interfaces.</p>
<p>We also analyzed structural changes across the whole Fab caused by the hapten antigen binding, and four different classifications of behavior were identified:<list list-type="simple">
<list-item>
<p>B1: The hapten binding causes deformation of the diamond-like Fab structure as well as prominent changes in the C_Loop<sub>1</sub> region indicating a potential allosteric signal propagation.</p>
</list-item>
<list-item>
<p>B2: The hapten binding does not deform the entire Fab but does still induce changes at the C_Loop<sub>1</sub>.</p>
</list-item>
<list-item>
<p>B3: The effects of the hapten binding are restricted to local changes to the&#x20;CDRs.</p>
</list-item>
<list-item>
<p>B4: Only minor structural changes throughout the Fab are caused by the hapten binding.</p>
</list-item>
</list>
</p>
<p>These classifications align well with those we found for protein-binding Fabs (<xref ref-type="bibr" rid="B4">Al Qaraghuli et&#x20;al., 2020</xref>) lending weight to our interpretation that potential structural changes must be specifically addressed in the development of novel therapeutics. Our focus on the cocaine-hydrolyzing antibody revealed it to be class B3, which can be understood in that the functionality does not require structural changes to affect further immunological responses. Finally, class B4 is new to the hapten antigens, but perhaps is not unexpected if the binding is relatively weak. We have found that there is some weak correlation between the binding surface classification S2 (where a pocket at the Fab binding surface is removed upon hapten binding) and the absence of potential structural changes in&#x20;B3.</p>
<p>From this study, we recommend a careful analysis of the entire antibody structure, and not just the binding surfaces in isolation, and correlate them to structural changes throughout the antibody. This will undoubtedly enable the identification of long-range structural changes that have the potential to induce an Fc effector response. This study could be extended in the future by utilizing molecular dynamics simulation to analyze the movements of a sample antibody to identify such long-range movements.</p>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="sec" rid="s9">Supplementary Material</xref>, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s6">
<title>Author Contributions</title>
<p>MA selected and retrieved the crystal structures from PDB, performed the sequence and structural analysis, and lead the manuscript development. KK-O contributed to structural analysis (RMSD/RMSF) and data interpretations. VF has contributed to data interpretations; and PM has supervised the overall project and data interpretations. All authors contributed to the development of the manuscript.</p>
</sec>
<sec id="s7">
<title>Funding</title>
<p>We acknowledge financial support from EPSRC Grant No. EP/R51178X/1.</p>
</sec>
<sec sec-type="COI-statement" id="s8">
<title>Conflict of Interest</title>
<p>Author MQ was employed by the SiMologics&#x20;Ltd.</p>
<p>The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<ack>
<p>Structural analysis was performed using the ARCHIE-WeSt High Performance Computer (<ext-link ext-link-type="uri" xlink:href="http://www.archie-west.ac.uk">www.archie-west.ac.uk</ext-link>) based at the University of Strathclyde.</p>
</ack>
<sec id="s9">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmolb.2021.633526/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fmolb.2021.633526/full&#x23;supplementary-material</ext-link>.</p>
<supplementary-material xlink:href="datasheet1.pdf" id="SM1" mimetype="application/pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abhinandan</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>A. C. R.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Analysis and prediction of V<sub>H</sub>/V<sub>L</sub> packing in antibodies</article-title>. <source>Protein Eng. Des. Sel.</source> <volume>23</volume>, <fpage>689</fpage>&#x2013;<lpage>697</lpage>. <pub-id pub-id-type="doi">10.1093/protein/gzq043</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adachi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kurihara</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nojima</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Takeda-Shitaka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kamiya</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Umeyama</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Interaction between the antigen and antibody is controlled by the constant domains: normal mode dynamics of the HEL-HyHEL-10 complex</article-title>. <source>Protein Sci.</source> <volume>12</volume>, <fpage>2125</fpage>&#x2013;<lpage>2131</lpage>. <pub-id pub-id-type="doi">10.1110/ps.03100803</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Addis</surname>
<given-names>P. W.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Bruton</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Veverka</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>I. C.</given-names>
</name>
<name>
<surname>Muskett</surname>
<given-names>F. W.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Conformational heterogeneity in antibody-protein antigen recognition</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>289</volume>, <fpage>7200</fpage>&#x2013;<lpage>7210</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M113.492215</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al Qaraghuli</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Kubiak-Ossowska</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ferro</surname>
<given-names>V. A.</given-names>
</name>
<name>
<surname>Mulheran</surname>
<given-names>P. A.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Antibody-protein binding and conformational changes: identifying allosteric signalling pathways to engineer a better effector response</article-title>. <source>Sci. Rep.</source> <volume>10</volume> (<issue>1</issue>), <fpage>13696</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-020-70680-0</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al Qaraghuli</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Kubiak-Ossowska</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mulheran</surname>
<given-names>P. A.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Thinking outside the laboratory: analyses of antibody structure and dynamics within different solvent environments in molecular dynamics (MD) simulations</article-title>. <source>Antibodies</source> <volume>7</volume>, <fpage>21</fpage>. <pub-id pub-id-type="doi">10.3390/antib7030021</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al Qaraghuli</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Palliyil</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Broadbent</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cullen</surname>
<given-names>D. C.</given-names>
</name>
<name>
<surname>Charlton</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>A. J.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Defining the complementarities between antibodies and haptens to refine our understanding and aid the prediction of a successful binding interaction</article-title>. <source>BMC Biotechnol.</source> <volume>15</volume> (<issue>1</issue>), <fpage>99</fpage>. <pub-id pub-id-type="doi">10.1186/s12896-015-0217-x</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Alberts</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Raff</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2002</year>). &#x201c;<article-title>B&#x20;cells and antibodies</article-title>,&#x201d; in <source>Molecular biology of the cell</source>. <edition>4th Edn</edition>, Editors <person-group person-group-type="editor">
<name>
<surname>Alberts</surname>
<given-names>B.</given-names>
</name>
</person-group> (<publisher-loc>New York, NY</publisher-loc>: <publisher-name>Garland Science</publisher-name>). </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Almagro</surname>
<given-names>J.&#x20;C.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Identification of differences in the specificity-determining residues of antibodies that recognize antigens of different size: implications for the rational design of antibody repertoires</article-title>. <source>J.&#x20;Mol. Recognit.</source> <volume>17</volume>, <fpage>132</fpage>&#x2013;<lpage>143</lpage>. <pub-id pub-id-type="doi">10.1002/jmr.659</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arevalo</surname>
<given-names>J.&#x20;H.</given-names>
</name>
<name>
<surname>Taussig</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>I. A.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Molecular basis of crossreactivity and the limits of antibody-antigen complementarity</article-title>. <source>Nature</source> <volume>365</volume>, <fpage>859</fpage>&#x2013;<lpage>863</lpage>. <pub-id pub-id-type="doi">10.1038/365859a0</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Backes</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Hotta</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hilvert</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Promiscuity in antibody catalysis: esterolytic activity of the decarboxylase 21D8</article-title>. <source>Helv. Chim. Acta</source> <volume>86</volume>, <fpage>1167</fpage>&#x2013;<lpage>1174</lpage>. <pub-id pub-id-type="doi">10.1002/hlca.200390101</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bentley</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Boulot</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Riottot</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Poljak</surname>
<given-names>R. J.</given-names>
</name>
</person-group> (<year>1990</year>). <article-title>Three-dimensional structure of an idiotope-anti-idiotope complex</article-title>. <source>Nature</source> <volume>348</volume>, <fpage>254</fpage>&#x2013;<lpage>257</lpage>. <pub-id pub-id-type="doi">10.1038/348254a0</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bosshard</surname>
<given-names>H. R.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Molecular recognition by induced fit: how fit is the concept?</article-title>. <source>Physiology</source> <volume>16</volume>, <fpage>171</fpage>&#x2013;<lpage>173</lpage>. <pub-id pub-id-type="doi">10.1152/physiologyonline.2001.16.4.171</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bowen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Casadevall</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Revisiting the immunoglobulin intramolecular signaling hypothesis</article-title>. <source>Trends Immunol.</source> <volume>37</volume>, <fpage>721</fpage>&#x2013;<lpage>723</lpage>. <pub-id pub-id-type="doi">10.1016/j.it.2016.08.014</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Braden</surname>
<given-names>B. C.</given-names>
</name>
<name>
<surname>Poljak</surname>
<given-names>R. J.</given-names>
</name>
</person-group> (<year>1995</year>). <article-title>Structural features of the reactions between antibodies and protein antigens</article-title>. <source>FASEB J.</source> <volume>9</volume>, <fpage>9</fpage>&#x2013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1096/fasebj.9.1.7821765</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bryson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Julien</surname>
<given-names>J.-P.</given-names>
</name>
<name>
<surname>Hynes</surname>
<given-names>R. C.</given-names>
</name>
<name>
<surname>Pai</surname>
<given-names>E. F.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications</article-title>. <source>J.&#x20;Virol.</source> <volume>83</volume>, <fpage>11862</fpage>&#x2013;<lpage>11875</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01604-09</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carugo</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Pongor</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>A normalized root-mean-square distance for comparing protein three-dimensional structures</article-title>. <source>Protein Sci.</source> <volume>10</volume>, <fpage>1470</fpage>&#x2013;<lpage>1473</lpage>. <pub-id pub-id-type="doi">10.1110/ps.690101</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Debler</surname>
<given-names>E. W.</given-names>
</name>
<name>
<surname>M&#xfc;ller</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hilvert</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>I. A.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Conformational isomerism can limit antibody catalysis</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>283</volume>, <fpage>16554</fpage>&#x2013;<lpage>16560</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M710256200</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dimitrov</surname>
<given-names>J.&#x20;D.</given-names>
</name>
<name>
<surname>Lacroix-Desmazes</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kaveri</surname>
<given-names>S. V.</given-names>
</name>
<name>
<surname>Vassilev</surname>
<given-names>T. L.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Transition towards antigen-binding promiscuity of a monospecific antibody</article-title>. <source>Mol. Immunol.</source> <volume>44</volume>, <fpage>1854</fpage>&#x2013;<lpage>1863</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2006.10.002</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dimitrov</surname>
<given-names>J.&#x20;D.</given-names>
</name>
<name>
<surname>Pashov</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Vassilev</surname>
<given-names>T. L.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Antibody polyspecificity</article-title>. <source>Adv. Exp. Med. Biol.</source> <volume>750</volume>, <fpage>213</fpage>&#x2013;<lpage>226</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4614-3461-0_16</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foote</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Immunology: isomeric antibodies</article-title>. <source>Science</source> <volume>299</volume>, <fpage>1327</fpage>&#x2013;<lpage>1328</lpage>. <pub-id pub-id-type="doi">10.1126/science.1082717</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foote</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Milstein</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>Conformational isomerism and the diversity of antibodies</article-title>. <source>Proc. Natl. Acad. Sci.</source> <volume>91</volume>, <fpage>10370</fpage>&#x2013;<lpage>10374</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.91.22.10370</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hall</surname>
<given-names>T.</given-names>
</name>
</person-group>, <year>1999</year>. &#x201c;<article-title>BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT</article-title>,&#x201d; in <conf-name>Presented at the nucleic acids symposium series no. 41</conf-name> (<publisher-name>Oxford University Press</publisher-name>), <fpage>95</fpage>&#x2013;<lpage>98</lpage>. </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansson</surname>
<given-names>U.-B.</given-names>
</name>
<name>
<surname>Wingren</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Alkner</surname>
<given-names>U.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Conformational isomerism of IgG antibodies</article-title>. <source>Biochim. Biophys. Acta (BBA) Protein Struct. Mol. Enzymol.</source> <volume>1340</volume>, <fpage>53</fpage>&#x2013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/s0167-4838(97)00028-9</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holdsworth</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Slocombe</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Doyle</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sweeney</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Veverka</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Le Riche</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>287</volume>, <fpage>26464</fpage>&#x2013;<lpage>26477</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112.350108</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horgan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pincus</surname>
<given-names>S. H.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>Effect of H chain V region on complement activation by immobilized immune complexes</article-title>. <source>J.&#x20;Immunol.</source> <volume>149</volume>, <fpage>127</fpage>&#x2013;<lpage>135</lpage>. </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Irani</surname>
<given-names>S. R.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>&#x2018;Moonlighting&#x2019; surface antigens: a paradigm for autoantibody pathogenicity in neurology?</article-title>. <source>Brain</source> <volume>139</volume>, <fpage>304</fpage>&#x2013;<lpage>306</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awv364</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacob</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kelsoe</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rajewsky</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>U.</given-names>
</name>
</person-group> (<year>1991</year>). <article-title>Intraclonal generation of antibody mutants in germinal centres</article-title>. <source>Nature</source> <volume>354</volume>, <fpage>389</fpage>&#x2013;<lpage>392</lpage>. <pub-id pub-id-type="doi">10.1038/354389a0</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>James</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>Tawfik</surname>
<given-names>D. S.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>The specificity of cross-reactivity: promiscuous antibody binding involves specific hydrogen bonds rather than nonspecific hydrophobic stickiness</article-title>. <source>Protein Sci.</source> <volume>12</volume>, <fpage>2183</fpage>&#x2013;<lpage>2193</lpage>. <pub-id pub-id-type="doi">10.1110/ps.03172703</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>James</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>Roversi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Tawfik</surname>
<given-names>D. S.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Antibody multispecificity mediated by conformational diversity</article-title>. <source>Science</source> <volume>299</volume>, <fpage>1362</fpage>&#x2013;<lpage>1367</lpage>. <pub-id pub-id-type="doi">10.1126/science.1079731</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Warren</surname>
<given-names>A. S.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Enthalpy-entropy compensation in the transition of a monospecific antibody towards antigen-binding promiscuity</article-title>. <source>Mol. Immunol.</source> <volume>44</volume>, <fpage>3623</fpage>&#x2013;<lpage>3624</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2007.03.006</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keitel</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kramer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wessner</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Scholz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schneider-Mergener</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hohne</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>1997</year>). <article-title>Crystallographic analysis of anti-p24 (HIV-1) monoclonal antibody cross-reactivity and polyspecificity</article-title>. <source>Cell</source> <volume>91</volume>, <fpage>811</fpage>&#x2013;<lpage>820</lpage>. <pub-id pub-id-type="doi">10.1016/S0092-8674(00)80469-9</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keskin</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Binding induced conformational changes of proteins correlate with their intrinsic fluctuations: a case study of antibodies</article-title>. <source>BMC Struct. Biol.</source> <volume>7</volume>, <fpage>31</fpage>. <pub-id pub-id-type="doi">10.1186/1472-6807-7-31</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krishnan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sahni</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Salunke</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Role of antibody paratope conformational flexibility in the manifestation of molecular mimicry</article-title>. <source>Biophys. J.</source> <volume>94</volume>, <fpage>1367</fpage>&#x2013;<lpage>1376</lpage>. <pub-id pub-id-type="doi">10.1529/biophysj.107.108654</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kubota</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Niwa</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Satoh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Akinaga</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shitara</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hanai</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Engineered therapeutic antibodies with improved effector functions</article-title>. <source>Cancer Sci.</source> <volume>100</volume>, <fpage>1566</fpage>&#x2013;<lpage>1572</lpage>. <pub-id pub-id-type="doi">10.1111/j.1349-7006.2009.01222.x</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacCallum</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>A. C. R.</given-names>
</name>
<name>
<surname>Thornton</surname>
<given-names>J.&#x20;M.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Antibody-antigen interactions: contact analysis and binding site topography</article-title>. <source>J.&#x20;Mol. Biol.</source> <volume>262</volume>, <fpage>732</fpage>&#x2013;<lpage>745</lpage>. <pub-id pub-id-type="doi">10.1006/jmbi.1996.0548</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacLennan</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>1991</year>). <article-title>Immunology. The centre of hypermutation</article-title>. <source>Nature</source>, <volume>354</volume>, <fpage>352</fpage>&#x2013;<lpage>353</lpage>. <pub-id pub-id-type="doi">10.1038/354352a0</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>A. C. R.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Structural biology of moonlighting: lessons from antibodies</article-title>. <source>Biochem. Soc. Trans.</source> <volume>42</volume>, <fpage>1704</fpage>&#x2013;<lpage>1708</lpage>. <pub-id pub-id-type="doi">10.1042/BST20140211</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McDonald</surname>
<given-names>I. K.</given-names>
</name>
<name>
<surname>Thornton</surname>
<given-names>J.&#x20;M.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>Satisfying hydrogen bonding potential in proteins</article-title>. <source>J.&#x20;Mol. Biol.</source> <volume>238</volume>, <fpage>777</fpage>&#x2013;<lpage>793</lpage>. <pub-id pub-id-type="doi">10.1006/jmbi.1994.1334</pub-id> </citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muramatsu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kinoshita</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fagarasan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shinkai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Honjo</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme</article-title>. <source>Cell</source> <volume>102</volume>, <fpage>553</fpage>&#x2013;<lpage>563</lpage>. <pub-id pub-id-type="doi">10.1016/s0092-8674(00)00078-7</pub-id> </citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Padlan</surname>
<given-names>E. A.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>Anatomy of the antibody molecule</article-title>. <source>Mol. Immunol.</source> <volume>31</volume>, <fpage>169</fpage>&#x2013;<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1016/0161-5890(94)90001-9</pub-id> </citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patil</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kinoshita</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Domain distribution and intrinsic disorder in hubs in the human protein-protein interaction network</article-title>. <source>Protein Sci.</source> <volume>19</volume>, <fpage>1461</fpage>&#x2013;<lpage>1468</lpage>. <pub-id pub-id-type="doi">10.1002/pro.425</pub-id> </citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piekarska</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Drozd</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Konieczny</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kr&#xf3;l</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jurkowski</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Roterman</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>The indirect generation of long-distance structural changes in antibodies upon their binding to antigen</article-title>. <source>Chem. Biol. Drug Des.</source> <volume>68</volume>, <fpage>276</fpage>
<italic>&#x2013;</italic>
<lpage>283</lpage>. <pub-id pub-id-type="doi">10.1111/j.1747-0285.2006.00448.x</pub-id> </citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pokkuluri</surname>
<given-names>P. R.</given-names>
</name>
<name>
<surname>Bouthillier</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kuderova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cygler</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>Preparation, characterization and crystallization of an antibody Fab fragment that recognizes RNA</article-title>. <source>J.&#x20;Mol. Biol.</source> <volume>243</volume>, <fpage>283</fpage>&#x2013;<lpage>297</lpage>. <pub-id pub-id-type="doi">10.1006/jmbi.1994.1654</pub-id> </citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Porter</surname>
<given-names>R. R.</given-names>
</name>
</person-group> (<year>1959</year>). <article-title>The hydrolysis of rabbit &#x3b3;-globulin and antibodies with crystalline papain</article-title>. <source>Biochem. J.</source> <volume>73</volume>, <fpage>119</fpage>&#x2013;<lpage>127</lpage>. <pub-id pub-id-type="doi">10.1042/bj0730119</pub-id> </citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pritsch</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Hudry-Clergeon</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Buckle</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Petillot</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Bouvet</surname>
<given-names>J.&#x20;P.</given-names>
</name>
<name>
<surname>Gagnon</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>1996</year>). <article-title>Can immunoglobulin C(H)1 constant region domain modulate antigen binding affinity of antibodies?</article-title>. <source>J.&#x20;Clin. Invest.</source> <volume>98</volume>, <fpage>2235</fpage>&#x2013;<lpage>2243</lpage>. <pub-id pub-id-type="doi">10.1172/JCI119033</pub-id> </citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pritsch</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Magnac</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dumas</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bouvet</surname>
<given-names>J.-P.</given-names>
</name>
<name>
<surname>Alzari</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Dighiero</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2000</year>). <article-title>Can isotype switch modulate antigen-binding affinity and influence clonal selection?</article-title>. <source>Eur. J.&#x20;Immunol.</source> <volume>30</volume>, <fpage>3387</fpage>&#x2013;<lpage>3395</lpage>. <pub-id pub-id-type="doi">10.1002/1521-4141(2000012)30:12&#x3c;3387::AID-IMMU3387&#x3e;3.0.CO;2-K</pub-id> </citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raghunathan</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Smart</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Almagro</surname>
<given-names>J.&#x20;C.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Antigen-binding site anatomy and somatic mutations in antibodies that recognize different types of antigens</article-title>. <source>J.&#x20;Mol. Recognit.</source> <volume>25</volume>, <fpage>103</fpage>&#x2013;<lpage>113</lpage>. <pub-id pub-id-type="doi">10.1002/jmr.2158</pub-id> </citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rini</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Schulze-Gahmen</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>1992</year>). <article-title>Structural evidence for induced fit as a mechanism for antibody-antigen recognition</article-title>. <source>Science</source> <volume>255</volume>, <fpage>959</fpage>&#x2013;<lpage>965</lpage>. <pub-id pub-id-type="doi">10.1126/science.1546293</pub-id> </citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosen</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Chill</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sharon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kessler</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mester</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zolla-Pazner</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization</article-title>. <source>Biochemistry</source> <volume>44</volume>, <fpage>7250</fpage>&#x2013;<lpage>7258</lpage>. <pub-id pub-id-type="doi">10.1021/bi047387t</pub-id> </citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryle</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>R. R.</given-names>
</name>
</person-group> (<year>1959</year>). <article-title>Parapepsins: two proteolytic enzymes associated with porcine pepsin</article-title>. <source>Biochem. J.</source> <volume>73</volume>, <fpage>75</fpage>&#x2013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1042/bj0730075</pub-id> </citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sela-Culang</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Alon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ofran</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>A systematic comparison of free and bound antibodies reveals binding-related conformational changes</article-title>. <source>J.&#x20;Immunol.</source> <volume>189</volume>, <fpage>4890</fpage>&#x2013;<lpage>4899</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1201493</pub-id> </citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tapryal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gaur</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Salunke</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Structural evaluation of a mimicry-recognizing paratope: plasticity in antigen-antibody interactions manifests in molecular mimicry</article-title>. <source>J.&#x20;Immunol.</source> <volume>191</volume>, <fpage>456</fpage>&#x2013;<lpage>463</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1203260</pub-id> </citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torres</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ferna&#xe9;ndez-Fuentes</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Fiser</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Casadevall</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>The immunoglobulin heavy chain constant region affects kinetic and thermodynamic parameters of antibody variable region interactions with antigen</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>282</volume>, <fpage>13917</fpage>&#x2013;<lpage>13927</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M700661200</pub-id> </citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Oss</surname>
<given-names>C. J.</given-names>
</name>
</person-group> (<year>1995</year>). <article-title>Hydrophobic, hydrophilic and other interactions in epitope-paratope binding</article-title>. <source>Mol. Immunol.</source> <volume>32</volume>, <fpage>199</fpage>&#x2013;<lpage>211</lpage>. <pub-id pub-id-type="doi">10.1016/0161-5890(94)00124-j</pub-id> </citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veverka</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Henry</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Slocombe</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Ventom</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mulloy</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Muskett</surname>
<given-names>F. W.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Characterization of the structural features and interactions of sclerostin</article-title>. <source>J.&#x20;Biol. Chem.</source> <volume>284</volume>, <fpage>10890</fpage>&#x2013;<lpage>10900</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M807994200</pub-id> </citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Conformational selection and induced fit in specific antibody and antigen recognition: SPE7 as a case study</article-title>. <source>J.&#x20;Phys. Chem. B</source> <volume>117</volume>, <fpage>4912</fpage>&#x2013;<lpage>4923</lpage>. <pub-id pub-id-type="doi">10.1021/jp4010967</pub-id> </citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waters</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>Veverka</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>B&#xf6;hm</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schmedt</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Choong</surname>
<given-names>P. T.</given-names>
</name>
<name>
<surname>Muskett</surname>
<given-names>F. W.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>Structure of the C-terminal MA-3 domain of the tumour suppressor protein Pdcd4 and characterization of its interaction with eIF4A</article-title>. <source>Oncogene</source> <volume>26</volume>, <fpage>4941</fpage>&#x2013;<lpage>4950</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1210305</pub-id> </citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Webster</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Henry</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Rees</surname>
<given-names>A. R.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>Antibody-antigen interactions</article-title>. <source>Curr. Opin. Struct. Biol.</source> <volume>4</volume>, <fpage>123</fpage>&#x2013;<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1016/S0959-440X(94)90070-1</pub-id> </citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>I. A.</given-names>
</name>
<name>
<surname>Stanfield</surname>
<given-names>R. L.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>Antibody-antigen interactions: new structures and new conformational changes</article-title>. <source>Curr. Opin. Struct. Biol.</source> <volume>4</volume>, <fpage>857</fpage>&#x2013;<lpage>867</lpage>. <pub-id pub-id-type="doi">10.1016/0959-440X(94)90267-4</pub-id> </citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kroe-Barrett</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Laue</surname>
<given-names>T. M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>IgG cooperativity&#x2014;is there allostery? implications for antibody functions and therapeutic antibody development</article-title>. <source>mAbs</source> <volume>9</volume>, <fpage>1231</fpage>&#x2013;<lpage>1252</lpage>. <pub-id pub-id-type="doi">10.1080/19420862.2017.1367074</pub-id> </citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Dickerson</surname>
<given-names>T. J.</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Kaufmann</surname>
<given-names>G. F.</given-names>
</name>
<name>
<surname>Mee</surname>
<given-names>J.&#x20;M.</given-names>
</name>
<name>
<surname>McKenzie</surname>
<given-names>K. M.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Complete reaction cycle of a cocaine catalytic antibody at atomic resolution</article-title>. <source>Structure</source> <volume>14</volume>, <fpage>205</fpage>&#x2013;<lpage>216</lpage>. <pub-id pub-id-type="doi">10.1016/j.str.2005.10.014</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>